CSI Market
Sign In | Register

Sarepta Therapeutics Inc (SRPT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SRPT Annual Cash Flow →
Reviewing cash flow figures over time highlights how Sarepta Therapeutics Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income691.82
Depreciation & amortization21.00
Amortization of Other Assets1.41
Increase (Decrease) in Deferred Revenue-307.04
Impairment of Real Estate0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories41.45
Research and Development in Process0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation53.90
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gain Loss On Disposal Of Assets-
Available For Sale Securities Gross Realized Gains-
Impairment Of Investments-
Conversion Of Interest Accrued To Common Stock-
Increase Decrease On Warrant Valuation-
Increase Decrease In Accounts Receivable And Other Current Assets-
Issuance Of Common Stock And Warrants In Satisfaction Of Liabilities-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Noncash Or Part Noncash Acquisition Fixed Assets Acquired5.95
Noncash Or Part Noncash Acquisition Intangible Assets Acquired-
Amortization Of Investment Premium Or Discount-
Non Cash Up Front Payment-
Reduction In The Carrying Amounts Of The Right Of Use Assets3.11
Available For Sale Securities Transfers To Trading Gross Gains-
Non Cash Inventory Write Downs For Excess And Obsolescence-
Non Cash Payment To Arrowhead Pharmaceuticals-
Loss On Investment In Arrowhead Pharmaceuticals-
Accretion Of Investment Discount Net-0.53
Increase Decrease In Manufacturing Related Deposits And Prepaids43.49
Income taxes0.00
Gain (Loss) on Investments-2.16
Increase (Decrease) in Accounts Receivable-21.41
Increase (Decrease) in Accounts Payable-229.86
Accrued Expense-34.69
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-67.84
Other Noncash Income (Expense)1.30
Other net0.00
Payments for (Proceeds from) Other Operating Activities-153.48
Discontinued operations0.00
Net Cash flow from Operating Activities-5.61
Investing Activities
Capital Expenditures-3.64
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities126.92
Payments to Acquire Available-for-sale Securities, Debt0.00
Payments for Tenant Improvements0.00
Acquisition Costs-
Other Investing Activity-
Acquisition Of Strategic Investments-
Proceeds from Sale of Restricted Investments0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Investment Projects-351.05
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-227.76
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.24
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Withdrawal Of Partnership Net Assets-
Proceeds From Exercise Of Options And Warrants-
Proceeds From Exercise Of Options And Warrants And Employee Stock Purchase Program-
Payment Of Term Loan-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Purchase Of Capped Call Options-
Taxes Paid Related To Net Share Settlement Of Equity Awards-
Repayment Of Term Loan-
Proceeds From Sales Of Common Stock Net Of Offering Costs-
Repurchase Of Debt-
Purchase Of Capped Call Share Options For2027 Notes-
Partial Settlement Of Capped Call Share Options For2024 Notes-
Debt Issuance Costs For2019 Term Loan-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.24
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-9.25
Total Cash Flow-233.13
4 historic quarters locked

Sign in to unlock the full Sarepta Therapeutics Inc cash flow history.

Sign In Create Free Account

About Sarepta Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-335003

Figures are derived from filed reports and may be restated. Historical data is subject to revision.